Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Daily Aspirin May Reduce Risk of Liver Cancer in Patients with HBV

Publish date:: March 25, 2019

Key clinical point: For patients with chronic hepatitis B, daily aspirin therapy may reduce the risk of hepatocellular carcinoma.

Major finding: Daily aspirin therapy reduced the risk of hepatocellular carcinoma by 29%.

Study details: A cohort study involving 2,123 patients with chronic hepatitis B who received daily aspirin and 8,492 matched controls.

Disclosures: The study was funded by the Ministry of Science and Technology, National Health Research Institutes, and Taichung (Taiwan) Veterans General Hospital. One author reported financial compensation from Gilead and Bristol-Myers Squibb.

Citation:

Lee T-Y et al. JAMA Intern Med. 2019 Mar 18. doi: 10.1001/jamainternmed.2018.8342.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gastroenterology

Younger adults present with more advanced esophageal adenocarcinoma,

DOACs look safe in elective endoscopic procedures,

Upper GI bleeds in COVID-19 not related to increased mortality,

Cryoballoon, cryospray found equivalent for eradicating Barret’s esophagus,